Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
The company had reported earnings of 14 cents per share in the year-ago quarter. Revenues increased 39% year over year to $146.8 million. The figure beat the Zacks Consensus Estimate of $138 million. The top line solely comprises product sales of Cushing's syndrome drug, Korlym. Quarter in Detail Revenues from Korlym beat our model estimate of $129.8 million. Research and development expenses surged 43% year over year to $58.5 million. Selling, general and administrative expenses increased around 15.8% year over year to $56.3 million. Consequently, operating expenses increased to $117.3 million, up 29.2% from the year-ago quarter's level, owing to higher expenses to support ongoing clinical studies. Corcept's shares have lost 26.4% so far this year compared with the industry decline of 10.2%. Image Source: Zacks Investment Research Cash and investments, as of Mar 31, 2024, totaled $451 million compared with $425.4 million as of Dec 31, 2023. 2024 Guidance Corcept
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- 3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70% [Yahoo! Finance]Yahoo! Finance
- Pipeline Moves: Phase III completion for Corcept's relaorilant [Yahoo! Finance]Yahoo! Finance
- Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $38.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
CORT
Earnings
- 5/1/24 - Beat
CORT
Analyst Actions
- 4/23/24 - HC Wainwright
CORT
Sec Filings
- 5/15/24 - Form 4
- 5/13/24 - Form 4
- 5/13/24 - Form 144
- CORT's page on the SEC website